Performance of the collaborative commercialization strategy: Strategic alliance
Introduction: The biopharmaceutical industry has several notable characteristics such as high R&D costs of $ 125 million to $ 250 million per drug, long-term commercialization cycles, and very complex and often long-term legislative procedures. All of these are associated with a high level of in...
Main Authors: | Roya Shakeri, Noormohammad Yaghoubi |
---|---|
Format: | Article |
Language: | fas |
Published: |
Yazd University
2022-01-01
|
Series: | کاوشهای مدیریت بازرگانی |
Subjects: | |
Online Access: | http://bar.yazd.ac.ir/article_2620_d50b5437ebb9a32e99bf13772de78109.pdf |
Similar Items
-
Study of firm-level strategic alliances drivers; case study Pharmaceutical industry
Published: (2015-05-01) -
The Model of Performance Predictors of Independent Commercialization Strategy in the Iranian Bio-Pharmaceutical Industry
by: Roya Shakeri, et al.
Published: (2022-11-01) -
Researching strategic alliances : emerging perspectives /
by: Das, T. K. (Tushar Kanti), 1938-
Published: (c201) -
The strategic alliance handbook : apractitioners guide to business-to-business collaborations /
by: 581704 Nevin, Mike author
Published: (2014) -
Factors of the Formation of Strategic Alliances
by: Orlov Vasyl M., et al.
Published: (2019-12-01)